New directions in the treatment of insomnia

Bibliography

• 2002 Sleep In America' Poll. National Sleep Foundation, Washington DC, USA (2002): 1–43.
   Google Scholar
• •Epidemiological study that recently estimated the prevalence of insomnia in the general population.
   Google Scholar
• FOLEY DJ, MONJAN AA, BROWN SL, SIMONSICK EM, WALLACE RB, BLAZER DG: Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep (1995):425–432.
   PubMedGoogle Scholar
• •Epidemiological study considered the best estimation of the prevalence of sleep complaints among elderly people.
   Google Scholar
• FOLEY DJ, MONJAN A. IZMIRLIAN G, HAYS JC, BLAZER DG: Incidence and remission of insomnia among elderly adults in a biracial cohort. Sktp (Supp1.2):5373-5378.
   Google Scholar
• 2003 Sleep In America' Poll. National Sleep Foundation, Washington DC, USA (2003): 1–46.
   Google Scholar
• FOLEY D, ANCOLI-ISRAEL S, BRITZ P, WALSH J: Sleep disturbances and chronic disease in older adults. Results of the 2003 National Sleep Foundation Sleep in America Survey./ Psychosomat. Res. (2004) 56:497–502.
   Google Scholar
• MARTIN SA, AIKENS JE, CHERVIN RD: Toward cost-effectiveness analysis in the diagnosis and treatment of insomnia. Sleep Med. Rev. (2004) 8:63–72.
   PubMed Web of Science ®Google Scholar
• WALSH J, ENGELHARDT C: The direct economic costs of insomnia in the United States for 1995. Sleep (1999) 22\(Supp1.2):5386–5393.
   Google Scholar
• Diagnostic and Statistical Manual of Mental Disorders (DSM-M. American Psychiatric Association, Washington DC, USA (1994): 1–886.
   Google Scholar
• LICHSTEIN KL: Secondary insomnia. In: Treatment of late-life insomnia. Lichstein KL, Morin CM (Eds), Sage Publications, London (2000):279–319.
   Google Scholar
• AMERICAN SLEEP DISORDERS ASSOCIATION: International Classification of Sleep Disorders. Diagnostic and Coding Manual. American Sleep Disorders Association (2nd Edn), Rochester (2005).
   Google Scholar
• McCRAE CS, LICHSTEIN KL: Secondary insomnia: diagnostic challenges and intervention opportunities. Sleep Med. Rev. (2001) 5:7–61.
   PubMedGoogle Scholar
• MONTI JM: Primary and secondary insomnia: prevalence, causes and current therapeutics. Curr. Med. Chem. CNS Agents (2004) 4:119–137.
   Google Scholar
• •Recent review of currently available benzodiazepine and nonbenzodiazepine hypnotics.
   Google Scholar
• ASNIS GM, CHAKRABURTTY A, DUBOFF EA et al.: Zolpidem for persistent insomnia in SSRI-treated depressed patients. J. lin. Psychiatry (1999) 60:668–676.
   Google Scholar
• HARVEY SC: Hypnotics and sedatives: the barbiturates. In: The Pharmacological Basis of Therapeutics. Goodman LS, Gilman A (Eds), MacMillan, NY, USA (1975):102–125.
   Google Scholar
• MENDELSON WB, ROTH T, CASSELLA J et al.: The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit Meeting Symposium. Sleep Med. Rev. (2004) 8:7–17.
   Google Scholar
• ATACK JR: Anxioselective compounds acting at the GABAA receptor benzodiazepine binding site. Cuff. Drug Targets - CNS NeuroL Disord. (2003) 2:213–232.
   PubMedGoogle Scholar
• PAUL SM: GABA and glycine. In: Psychopharmacology: The Fourth Generation of Progress. Bloom FE, Kupfer DJ (Eds), Raven Press, NY, USA (1995):87–94.
   Google Scholar
• ROWLETT JK, PLATT DM, LELAS S, ATACK JR, DAWSON GR: Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc. Natl. Acad. Sci. USA (2005) 102:915–920.
   PubMed Web of Science ®Google Scholar
• •The study provides evidence of the different roles of a subunits.
   Google Scholar
• GRAHAM D, BESNARD F, FAURE C, LANGER SZ: GABAA receptor subtype diversity: implications for new generation hypnotic drug discovery. Sleep (1996) 19:S43–S45.
   Google Scholar
• TEUBER L, WATJEN F, JENSEN LH: Ligands for the benzodiazepine binding site - a survey. Curr. Pharm. Design (1999) 5:317–343.
   PubMedGoogle Scholar
• ATOR NA, McCANN UD: New insights into the GABAA receptor. CNS Spectrums (2005) 10:20.
   Google Scholar
• McKERNAN RM, WHITING PJ: Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci. (1996) 19:139–143.
   Google Scholar
• LOW K, CRESTANI F, KEIST R et al.: Molecular and neuronal substrate for the selective attenuation of anxiety. Science (2000) 290:131–134.
   PubMed Web of Science ®Google Scholar
• SANGER DJ: The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs (2004) 18 (Supp1.1):9–15.
   Google Scholar
• CHARNEY DS, MIHIC SJ, HARRIS RA: Hypnotics and sedatives. In: The Pharmacological Basis of Therapeutics. Hardman JG, Limbird LE (Eds), McGraw-Hill, NY, USA (2001):399–427.
   Google Scholar
• GREENBLATT DJ: Benzodiazepine hypnotics: sorting the pharmacokinetic facts. Clin. Psychiatry (1991) 52(Suppl.):4–10.
   Google Scholar
• MONTI JM: Pharmacology of the histaminergic system. In: The Pharmacology of Sleep. Kales A (Ed.), Springer, Berlin, Germany (1995):117–142.
   Google Scholar
• MONTI JM, PELLEJERO T, JANTOS H: Effects of H1- and H2-histamine receptor agonists and antagonists on sleep and wakefulness in the rat. J. Neural Transm. (1986) 66:1–11.
   PubMed Web of Science ®Google Scholar
• MONTI JM, MONTI D: Histamine H1 receptor antagonists in the treatment of insomnia. Is there a rational basis for use? CNS Drugs (2000) 13:87–96.
   Google Scholar
• ••Extensive review of the relevance of sedative antihistamines in the treatment of insomnia.
   Google Scholar
• ROSENTHAL L, ROEHRS TA, PAXTON J et al.: Tolerance to the sedative effects of antihistamines. Sleep Res. (1995) 24:52.
   Google Scholar
• DUBOCOVICH ML, RIVERA -BERMUDEZ M, GERDIN MJ, MASANA MI: Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front. Biosci. (2003) 8:1093-1108. Recent review of the structure, function and pharmacology of melatonin receptors.
   Google Scholar
• ZHDANOVA IV WURTMAN RJ, LYNCH H et al.: Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin. PharmacoL Ther. (1995) 57:552–557.
   PubMedGoogle Scholar
• WURTMAN RJ, ZHDANOVA IV: Improvement of sleep quality by melatonin. Lancet (1995) 346:1491.
   PubMed Web of Science ®Google Scholar
• HUGHES JM, SACK RI,, LEWY AJ: The role of melatonin and circadian phase in age-related sleep maintenance insomnia: Assessment in a clinical trial of melatonin replacement. Sleep (1998) 21:52–68.
   PubMed Web of Science ®Google Scholar
• HAIMOV I, LAVIE P: Potential of melatonin replacement therapy in older patients with sleep disorders. Drugs Aging (1995) 7:75–78.
   PubMed Web of Science ®Google Scholar
• MONTI JM, ALVARIO F, CARDINALI D, SAVIO I, PINTOS k Polysomnographic study of the effect of melatonin on sleep in elderly patients with chronic primary insomnia. Arch. GerontoL Geriatrics (1999) 28:85–98.
   PubMed Web of Science ®Google Scholar
• MONTI JM, CARDINALI DP: A critical assessment of the melatonin effect on sleep in humans. Biol. Signals Recept. (2000) 9:328–339.
   PubMedGoogle Scholar
• HUGHES SP, SACK RL, LEWY AJ: The role of melatonin and circadian phase in age-related sleep maintenance insomnia: assessment in a clinical trial of melatonin replacement. Sleep (1998) 21:52
   PubMed Web of Science ®Google Scholar
• HAIMOV I, LAVIE P: Potential of melatoninreplacement therapy in older patients with sleep disorders. Drugs Aging (1995) 7:75–78.
   PubMed Web of Science ®Google Scholar
• MACFARLANE JG, CLEGHORN JM, BROWN GM, STREINER DL: The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study. Biol. Psychiatry (1991) 30:371–376.
   PubMed Web of Science ®Google Scholar
• FAINSTEIN I, BONETTO A. BRUSCO LI, CARDINALI DP: Effects of melatonin in elderly patients wih sleep disturbance. A pilot study. Curr. Ther. Res. (1997) 58:990–1000.
   Web of Science ®Google Scholar
• BRUSCO LI, MARQUEZ M, CARDINALI DP: Monozygotic twins with Alzheimer's disease treated with melatonin: case report. J. Pineal Res. (1998) 25:260–263.
   PubMed Web of Science ®Google Scholar
• LIEB K, AHLVERS K, DANCKER K et al.: Effects of the neuropeptide substance P on sleep, mood and neuroendocrine measures in healthy young men. Neuropsychopharmaco/ogy (2002) 27:1041–1049.
   PubMed Web of Science ®Google Scholar
• KUPFER DJ: Pathophysiology and management of insomnia during depression. Ann. Clin. Psychiat. (1999) 11:267–276
   PubMedGoogle Scholar
• STANER L, LUTHRINGER R, MACHER J-P: Effects of antidepressant drugs on sleep EEG in patients with major depression. CNS Drugs (1999) 11:49–60.
   Web of Science ®Google Scholar
• MENDELSON WB: A review of the evidence for the efficacy and safety of trazodone in insomnia. J. Clin. Psychiatr. (2005) 66:469–476.
   PubMed Web of Science ®Google Scholar
• JAMES SP, MENDELSON WB: The use of trazodone as a hypnotic: a critical review. J. Clin. Psychiatr. (2004) 65:752–755.
   PubMed Web of Science ®Google Scholar
• SALETU-ZYHLARZ GM, ABU -BAKR MH, ANDERER P et al.: Insomnia related to dysthymia: polysomnographic and psychometric comparison with normal controls and acute therapeutic trials with trazodone. Neuropsychobiology (2001) 44:139–149.
   PubMed Web of Science ®Google Scholar
• SALETU-ZYHLARZ GM, ABU -BAKR MH, ANDERER P et al: Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Frog. Neuropsychopharmacol. Biol. Psychiatry (2002) 26:249–260.
   PubMed Web of Science ®Google Scholar